# Elisigen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elisigen

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.elisigen.com/
- Total disclosed funding: $70M
- Latest round: Series C (Jan 19, 2026)
- Investors on record: 25

## About

Based in Seoul, South Korea, and founded in 2018, Elisigen Inc. operates as a biotechnology company that develops gene therapy to treat diseases through in vivo and ex vivo gene transfer methods. In January 2026, Elisigen Inc. raised KRW 5 billion in series C funding from NH Investment & Securities and DAYLI Partners, bringing the total amount raised in three series C rounds to KRW 42 billion.

Elisigen Inc. provides gene therapy products such as AAV vector-based gene therapy. The company also developed gene therapies for eye diseases such as age-related macular degeneration, chronic neuropathic pain, and cranial nerve diseases such as Alzheimer's disease. In addition, the firm focuses on developing NG101 for wet age-related macular degeneration and NG201 for neuropathic pain.

The company will use the January 2026 funding to support its clinical trials and international commercialization.

## Funding rounds

- Series C, Jan 19, 2026, $3.4M — NH Investment & Securities, DAYLI Partners
- Series C, Nov 3, 2025, $7.6M — Korea Development Bank
- Series C, Sep 8, 2025, $19M — KB Investment, Korea Investment Partners, Yuanta Investment, Premier Partners, IBK Capital, Seven Tree Equity Partners, NICE Investment Partners, Tigris Investment, Bilanx Investment
- Series B, Jun 3, 2021, $27M — Partners Investment, SV Investment, Saehan Venture Capital, Quad Asset Management, Seven Tree Equity Partners, Widwin Investment, Ryukyung PSG Asset Management Inc, Ulmus Investment, DAYLI Partners, DA Value Investment, Arche Investment, Aligned Genetics, Inc., LINKED VISION
- Series A, Apr 30, 2019, $14M — Partners Investment, Saehan Venture Capital, Quad Asset Management, Brahman Investment, Reyon Pharmaceutical Co., Ltd.

## Investors

- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Series A, Series B
- Saehan Venture Capital (https://capitalatlas.ai/funds/saehan-venture-capital) — Series A, Series B
- Quad Asset Management — Series A, Series B
- Brahman Investment — Series A
- Reyon Pharmaceutical Co., Ltd. — Series A
- SV Investment (https://capitalatlas.ai/funds/sv-investment) — Series B
- Seven Tree Equity Partners (https://capitalatlas.ai/funds/seven-tree-equity-partners) — Series B, Series C
- Widwin Investment (https://capitalatlas.ai/funds/widwin-investment) — Series B
- Ryukyung PSG Asset Management Inc — Series B
- Ulmus Investment (https://capitalatlas.ai/funds/ulmus-investment) — Series B
- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series B, Series C
- DA Value Investment (https://capitalatlas.ai/funds/da-value-investment) — Series B
- Arche Investment (https://capitalatlas.ai/funds/arche-investment) — Series B
- Aligned Genetics, Inc. — Series B
- LINKED VISION — Series B
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series C
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series C
- Yuanta Investment (https://capitalatlas.ai/funds/yuanta-investment) — Series C
- Premier Partners (https://capitalatlas.ai/funds/premier-partners) — Series C
- IBK Capital (https://capitalatlas.ai/funds/ibk-capital) — Series C
- NICE Investment Partners (https://capitalatlas.ai/funds/nice-investment-partners) — Series C
- Tigris Investment (https://capitalatlas.ai/funds/tigris-investment) — Series C
- Bilanx Investment (https://capitalatlas.ai/funds/bilanx-investment) — Series C
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series C
- NH Investment & Securities (https://capitalatlas.ai/funds/nh-investment-securities) — Series C